In the ATTRibute-CM open-label extension (n=389), acoramidis demonstrated sustained efficacy through 54 months, with early and continuous treatment significantly reducing all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization versus delayed initiation, while stabilizing NT-proBNP, functional capacity (6MWD), and quality of life (KCCQ-OS), without new safety signals—supporting early, continuous TTR stabilization as a disease-modifying strategy in ATTR-CM.